PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 7, 2012, Pages 1092-1101

  Wan, H T ^a   Zhao, Y G ^a   Wei, X ^a   Hui, K Y ^a   Giesy, J P ^b,c,d   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

oxidation; Fatty acid uptake; Lipid metabolism; Liver metabolism; Perfluorooctane sulfonate; Very low density lipoprotein

Indexed keywords

CD36 ANTIGEN; FATTY ACID; LIPOPROTEIN LIPASE; PERFLUOROOCTANESULFONIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; HEPATOMEGALY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIVER CELL; LIVER HISTOLOGY; LIVER MITOCHONDRION; LIVER TOXICITY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALKANESULFONIC ACIDS; ANIMALS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; BODY WEIGHT; FATTY ACIDS; FATTY LIVER; FLUOROCARBONS; LIPID METABOLISM; LIVER; MALE; MICE; ORGAN SIZE; OXIDATION-REDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIGLYCERIDES;

ANIMALIA; MUS;

EID: 84860821984     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.03.010     Document Type: Article

References (38)

1. A.G. Paul, K.C. Jones, and A.J. Sweetman A first global production, emission, and environmental inventory for perfluorooctane sulfonate Environ. Sci. Technol. 43 2009 386 392
2. G.W. Olsen, J.M. Burris, D.J. Ehresman, J.W. Froehlich, A.M. Seacat, J.L. Butenhoff, and L.R. Zobel Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers Environ. Health Perspect. 115 2007 1298 1305
3. C. Lau, K. Anitole, C. Hodes, D. Lai, A. Pfahles-Hutchens, and J. Seed Perfluoroalkyl acids: a review of monitoring and toxicological findings Toxicol. Sci. 99 2007 366 394
4. N. Kudo, E. Suzuki-Nakajima, A. Mitsumoto, and Y. Kawashima Responses of the liver to perfluorinated fatty acids with different carbon chain length in male and female mice: in relation to induction of hepatomegaly, peroxisomal beta-oxidation and microsomal 1-acylglycerophosphocholine acyltransferase Biol. Pharm. Bull. 29 2006 1952 1957
5. K.H. Harada, H.R. Yang, C.S. Moon, N.N. Hung, T. Hitomi, K. Inoue, T. Niisoe, T. Watanabe, S. Kamiyama, K. Takenaka, M.Y. Kim, K. Watanabe, T. Takasuga, and A. Koizumi Levels of perfluorooctane sulfonate and perfluorooctanoic acid in female serum samples from Japan in 2008, Korea in 1994-2008 and Vietnam in 2007-2008 Chemosphere 79 2010 314 319
6. A.M. Ingelido, V. Marra, A. Abballe, S. Valentini, N. Iacovella, P. Barbieri, M.G. Porpora, A. Domenico, and E. De Felip Perfluorooctanesulfonate and perfluorooctanoic acid exposures of the Italian general population Chemosphere 80 2010 1125 1130
7. K. Kato, L.Y. Wong, L.T. Jia, Z. Kuklenyik, and A.M. Calafat Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008 (dagger) Environ. Sci. Technol. 45 2011 8037 8045
8. W. Zhang, Z. Lin, M. Hu, X. Wang, Q. Lian, K. Lin, Q. Dong, and C. Huang Perfluorinated chemicals in blood of residents in Wenzhou, China Ecotoxicol. Environ. Saf. 74 2011 1787 1793
9. H.S. Kim, S. Jun Kwack, E. Sik Han, T. Seok Kang, S. Hee Kim, and S. Young Han Induction of apoptosis and CYP4A1 expression in Sprague-Dawley rats exposed to low doses of perfluorooctane sulfonate J. Toxicol. Sci. 36 2011 201 210
10. M.T. Martin, R.J. Brennan, W. Hu, E. Ayanoglu, C. Lau, H. Ren, C.R. Wood, J.C. Corton, R.J. Kavlock, and D.J. Dix Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity Toxicol. Sci. 97 2007 595 613
11. M.R. Qazi, M.R. Abedi, B.D. Nelson, J.W. DePierre, and M. Abedi-Valugerdi Dietary exposure to perfluorooctanoate or perfluorooctane sulfonate induces hypertrophy in centrilobular hepatocytes and alters the hepatic immune status in mice Int. Immunopharmacol. 10 2010 1420 1427
12. M.B. Rosen, J.E. Schmid, K.P. Das, C.R. Wood, R.D. Zehr, and C. Lau Gene expression profiling in the liver and lung of perfluorooctane sulfonate-exposed mouse fetuses: comparison to changes induced by exposure to perfluorooctanoic acid Reprod. Toxicol. 27 2009 278 288
13. J.A. Bjork, and K.B. Wallace Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures Toxicol. Sci. 111 2009 89 99
14. M.B. Rosen, J.R. Schmid, J.C. Corton, R.D. Zehr, K.P. Das, B.D. Abbott, and C. Lau Gene expression profiling in wild-type and PPARalpha-null mice exposed to perfluorooctane sulfonate reveals PPARalpha-independent effects PPAR Res. 2010 2010 1 23
15. M.L. Takacs, and B.D. Abbott Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate Toxicol. Sci. 95 2007 108 117
16. T.P. Carr, C.J. Andresen, and L.L. Rudel Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts Clin. Biochem. 26 1993 39 42
17. R.M. Machado, J.T. Stefano, C.P. Oliveira, E.S. Mello, F.D. Ferreira, V.S. Nunes, V.M. de Lima, E.C. Quintao, S. Catanozi, E.R. Nakandakare, and A.M. Lottenberg Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content J. Nutr. 140 2010 1127 1132
18. C. Chu, L.F. Mao, and H. Schulz Estimation of peroxisomal beta-oxidation in rat heart by a direct assay of acyl-CoA oxidase Biochem. J. 302 Pt 1 1994 23 29
19. X.X. Yu, J.K. Drackley, and J. Odle Rates of mitochondrial and peroxisomal beta-oxidation of palmitate change during postnatal development and food deprivation in liver, kidney and heart of pigs J. Nutr. 127 1997 1814 1821
20. C.H. Chen, M.H. Huang, J.C. Yang, C.K. Nien, C.C. Yang, Y.H. Yeh, and S.K. Yueh Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults J. Clin. Gastroenterol. 40 2006 745 752
21. M.R. Qazi, B.D. Nelson, J.W. Depierre, and M. Abedi-Valugerdi 28-Day dietary exposure of mice to a low total dose (7 mg/kg) of perfluorooctanesulfonate (PFOS) alters neither the cellular compositions of the thymus and spleen nor humoral immune responses: does the route of administration play a pivotal role in PFOS-induced immunotoxicity? Toxicology 267 2010 132 139
22. M.E. Austin, B.S. Kasturi, M. Barber, K. Kannan, P.S. MohanKumar, and S.M. MohanKumar Neuroendocrine effects of perfluorooctane sulfonate in rats Environ. Health Perspect. 111 2003 1485 1489
23. P. Angulo Nonalcoholic fatty liver disease N. Engl. J. Med. 346 2002 1221 1231
24. C. Carter-Kent, E.M. Brunt, L.M. Yerian, N. Alkhouri, P. Angulo, R. Kohli, S.C. Ling, S.A. Xanthakos, P.F. Whitington, P. Charatcharoenwitthaya, J. Yap, R. Lopez, A.J. McCullough, and A.E. Feldstein Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease J. Pediatr. Gastroenterol. Nutr. 52 2011 190 197
25. A.M. Seacat, P.J. Thomford, K.J. Hansen, L.A. Clemen, S.R. Eldridge, C.R. Elcombe, and J.L. Butenhoff Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats Toxicology 183 2003 117 131
26. D.G. Tiniakos Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems Eur. J. Gastroenterol. Hepatol. 22 2010 643 650
27. J.K. Reddy Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G1333 G1339
28. J.A. Bjork, C. Lau, S.C. Chang, J.L. Butenhoff, and K.B. Wallace Perfluorooctane sulfonate-induced changes in fetal rat liver gene expression Toxicology 251 2008 8 20
29. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
30. T. Hashimoto, W.S. Cook, C. Qi, A.V. Yeldandi, J.K. Reddy, and M.S. Rao Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting J. Biol. Chem. 275 2000 28918 28928
31. S.S. Choi, and A.M. Diehl Hepatic triglyceride synthesis and nonalcoholic fatty liver disease Curr. Opin. Lipidol. 19 2008 295 300
32. Q. Liu, S. Bengmark, and S. Qu The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD) Lipids Health Dis. 9 2010 42
33. M.W. Bradbury Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G194 G198
34. E. Fabbrini, S. Sullivan, and S. Klein Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications Hepatology 51 2010 679 689
35. C. Postic, and J. Girard Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice J. Clin. Invest. 118 2008 829 838
36. P.R. Holden, and J.D. Tugwood Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences J. Mol. Endocrinol. 22 1999 1 8
37. C.N. Palmer, M.H. Hsu, K.J. Griffin, J.L. Raucy, and E.F. Johnson Peroxisome proliferator activated receptor-alpha expression in human liver Mol. Pharmacol. 53 1998 14 22
38. A. Tailleux, K. Wouters, and B. Staels Roles of PPARs in NAFLD: potential therapeutic targets Biochim. Biophys. Acta 1821 2012 809 818